Kbc Group Nv Spero Therapeutics, Inc. Transaction History

Kbc Group Nv

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 07, 2019	SELL	$9.01 - $12.55 $62,484 - $87,034	-6,935 Closed	0 $0
Q2 2019 Dec 03, 2019	BUY	$10.25 - $14.36 $71,083 - $99,586	6,935 New	6,935 $80,000
Q2 2019 Jul 30, 2019	SELL	$10.25 - $14.36 $71,083 - $99,586	-6,935 Closed	0 $0
Q1 2019 Dec 03, 2019	BUY	$6.26 - $13.31 $43,413 - $92,304	6,935 New	6,935 $89,000
Q1 2019 May 10, 2019	SELL	$6.26 - $13.31 $43,413 - $92,304	-6,935 Closed	0 $0
Q4 2018 Dec 03, 2019	BUY	$5.69 - $11.28 $39,460 - $78,226	6,935 New	6,935 $43,000
Q4 2018 Jan 31, 2019	SELL	$5.69 - $11.28 $39,460 - $78,226	-6,935 Closed	0 $0
Q3 2018 Dec 03, 2019	BUY	$9.69 - $17.79 $67,200 - $123,373	6,935 New	6,935 $73,000

13.9M

200

200

Ticker SPRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,067,500
Market Cap $33.3M
Description
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to ...

Get notified when there are updates to the investment portfolio of Kbc Group Nv, based on Form 13F filings with the SEC.

Stay updated on Kbc Group Nv with notifications on news.